Cellectar Biosciences, Inc. (CLRB)

Over the past six months, Cellectar Biosciences reported its third-quarter 2025 financial results, exceeding analysts' expectations. The company announced a strategic supply agreement with Ionetix for Actinium-225 and Astatine-211. Cellectar Biosciences highlighted its strategic initiatives for 2026 at the JP Morgan Healthcare Conference. The U.S. FDA granted Rare Pediatric Disease Designation for iopofosine I 131 in inoperable relapsed or refractory pediatric high-grade glioma. The stock price has experienced significant volatility, decreasing by 40.88% over the last six months and 62.85% over the past year. The stock received an AI Score of 1/10, translating to a "Strong Sell" rating, and the consensus analyst rating is "Hold".

Information regarding specific demand seasonality for Cellectar Biosciences, Inc.'s products and services is not readily available. Demand for its products, once commercialized, would likely be driven by disease prevalence, treatment efficacy, regulatory approvals, and market access rather than traditional seasonal patterns.

Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical and radiopharmaceutical company focused on developing proprietary drugs for cancer treatment using its Phospholipid Drug Conjugate (PDC)™ delivery platform. The company's major product candidates include Iopofosine I 131, a small-molecule PDC being investigated for relapsed or refractory Waldenstrom's macroglobulinemia (WM), multiple myeloma, and pediatric brain tumors. CLR 125 (CLR 121125) is an iodine-125 Auger-emitting program targeting solid tumors, and CLR 225 (CLR 121225) is an actinium-225 based program aimed at solid tumors. The company also has preclinical PDC chemotherapeutic programs and partnered PDC assets.

Cellectar Biosciences, Inc. is headquartered in Florham Park, New Jersey, United States. While its primary operations are based in the U.S., the company is conducting a global clinical study for iopofosine I 131, indicating a broader international reach.

Cellectar Biosciences' brand reputation has been mixed. While the company received a Zacks Rank upgrade to "Buy" in July 2025, more recent assessments present a cautious view. Zacks Investment Research rated Cellectar Biosciences as a "Zacks Rank 3" (Hold), expecting an inline return relative to the market. MarketBeat's analysis shows a consensus analyst rating of "Hold" for the company. A proprietary AI model assigned a "Strong Sell" rating, citing high volatility and a lack of recent earnings reports. The Rare Pediatric Disease Designation for iopofosine I 131 could be seen as a positive development.

Major institutional owners of Cellectar Biosciences, Inc. include Bleichroeder LP, Vanguard Group Inc, Intracoastal Capital LLC, and Renaissance Technologies LLC. Individual insiders, such as John Neis, Chad Kolean, Jarrod Longcor, and James Caruso, have also engaged in stock transactions, with some insider buying observed in July 2025 and selling in December 2025.